Vertex Pharmaceuticals Inc. (VRTX)

209.80
NASDAQ : Health Technology
Prev Close 205.00
Day Low/High 205.01 / 210.05
52 Wk Low/High 151.80 / 207.64
Avg Volume 1.20M
Exchange NASDAQ
Shares Outstanding 257.15M
Market Cap 52.72B
EPS 8.20
P/E Ratio 24.82
Div & Yield N.A. (N.A)

Latest News

 Vertex Confirms Northern Ireland Offer Accepted For Cystic Fibrosis Medicines

 Vertex Confirms Northern Ireland Offer Accepted For Cystic Fibrosis Medicines

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirms that the Regional Pharmaceutical Procurement Service in Northern Ireland has accepted an offer for access to all currently licensed Vertex cystic fibrosis (CF) medicines and any future...

Vertex To Present At The Credit Suisse Healthcare Conference On November 12

Vertex To Present At The Credit Suisse Healthcare Conference On November 12

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2019 at 1:30 p.

Phase 3 Results From Two Studies Of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) Triple Combination Treatment For Cystic Fibrosis Concurrently Published In The New England Journal Of Medicine And The Lancet

Phase 3 Results From Two Studies Of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) Triple Combination Treatment For Cystic Fibrosis Concurrently Published In The New England Journal Of Medicine And The Lancet

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the concurrent publication in The New England Journal of Medicine (NEJM) and The Lancet of results from two Phase 3 studies of TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor)...

Vertex Announces European Medicines Agency Marketing Authorization Application Validation For VX-445 (Elexacaftor), Tezacaftor And Ivacaftor Triple Combination Treatment In Cystic Fibrosis

Vertex Announces European Medicines Agency Marketing Authorization Application Validation For VX-445 (Elexacaftor), Tezacaftor And Ivacaftor Triple Combination Treatment In Cystic Fibrosis

Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen.

Vertex Reports Third-Quarter 2019 Financial Results

Vertex Reports Third-Quarter 2019 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2019 and reiterated its full-year 2019 total product revenue guidance.

The Technical Profile of This Market Remains Positive

The Technical Profile of This Market Remains Positive

The indices are within striking distance of the July highs after moving into position for a possible strong finish to the year.

Vertex Announces Agreement With NHS England For Access To All Licensed Cystic Fibrosis Medicines

Vertex Announces Agreement With NHS England For Access To All Licensed Cystic Fibrosis Medicines

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an access agreement with NHS England for all currently licensed Vertex cystic fibrosis (CF) medicines and any future indications of these medicines.

Vertex To Announce Third-Quarter 2019 Financial Results On October 30

Vertex To Announce Third-Quarter 2019 Financial Results On October 30

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2019 financial results on Wednesday, October 30, 2019 after the financial markets close.

Spanish Government Approves National Reimbursement Of ORKAMBI® (lumacaftor/ivacaftor) And SYMKEVI® (tezacaftor/ivacaftor) In Combination With KALYDECO® (ivacaftor)

Spanish Government Approves National Reimbursement Of ORKAMBI® (lumacaftor/ivacaftor) And SYMKEVI® (tezacaftor/ivacaftor) In Combination With KALYDECO® (ivacaftor)

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor) in combination with KALYDECO ®...

 Vertex Announces Reimbursement Of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor And Ivacaftor) For Eligible Patients Ages 12 And Older, And ORKAMBI® (lumacaftor/ivacaftor) In Children Ages 2 To 5, With Certain CFTR Mutations In Australia

 Vertex Announces Reimbursement Of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor And Ivacaftor) For Eligible Patients Ages 12 And Older, And ORKAMBI® (lumacaftor/ivacaftor) In Children Ages 2 To 5, With Certain CFTR Mutations In Australia

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO ® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12 years and older who are homozygous for the F508del mutation or...

Vertex Receives European CHMP Positive Opinion For KALYDECO® (ivacaftor) To Treat Eligible Infants With Cystic Fibrosis As Early As 6 Months Of Age

Vertex Receives European CHMP Positive Opinion For KALYDECO® (ivacaftor) To Treat Eligible Infants With Cystic Fibrosis As Early As 6 Months Of Age

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO ® (ivacaftor), to include use in infants with cystic fibrosis...

Vertex Appoints Carmen Bozic, M.D., As New Chief Medical Officer And Nia Tatsis, Ph.D., As New Chief Regulatory Officer

Vertex Appoints Carmen Bozic, M.D., As New Chief Medical Officer And Nia Tatsis, Ph.D., As New Chief Regulatory Officer

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Carmen Bozic, M.

Vertex And Ribometrix Establish Strategic Collaboration To Discover And Develop RNA-Targeted Small Molecule Therapeutics

Vertex And Ribometrix Establish Strategic Collaboration To Discover And Develop RNA-Targeted Small Molecule Therapeutics

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and RNA therapeutics developer Ribometrix, Inc.

Vertex Announces New Access Agreement With Scottish Government For ORKAMBI® (lumacaftor/ivacaftor) And SYMKEVI® (tezacaftor/ivacaftor)

Vertex Announces New Access Agreement With Scottish Government For ORKAMBI® (lumacaftor/ivacaftor) And SYMKEVI® (tezacaftor/ivacaftor)

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that eligible cystic fibrosis patients living in Scotland will now have access to ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor) in combination with ivacaftor...

Vertex To Present At The Morgan Stanley Global Healthcare Conference On September 11

Vertex To Present At The Morgan Stanley Global Healthcare Conference On September 11

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 12:15 p.

FDA Accepts New Drug Application For VX-445 (Elexacaftor), Tezacaftor And Ivacaftor Combination Treatment

FDA Accepts New Drug Application For VX-445 (Elexacaftor), Tezacaftor And Ivacaftor Combination Treatment

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S.

Vertex Reports Second-Quarter 2019 Financial Results

Vertex Reports Second-Quarter 2019 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2019 and increased its full-year 2019 total product revenue guidance.

Vertex Announces Dr. Jeffrey Leiden To Transition To Role Of Executive Chairman, Effective April 1, 2020 And Dr. Reshma Kewalramani Appointed As New Chief Executive Officer

Vertex Announces Dr. Jeffrey Leiden To Transition To Role Of Executive Chairman, Effective April 1, 2020 And Dr. Reshma Kewalramani Appointed As New Chief Executive Officer

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its Board of Directors has approved the planned transition of Chairman, President and Chief Executive Officer Jeffrey Leiden, M.

Vertex Submits New Drug Application To The U.S. FDA For Triple Combination Regimen Of VX-445 (Elexacaftor), Tezacaftor And Ivacaftor In Cystic Fibrosis

Vertex Submits New Drug Application To The U.S. FDA For Triple Combination Regimen Of VX-445 (Elexacaftor), Tezacaftor And Ivacaftor In Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the submission of a New Drug Application (NDA) to the U.

Vertex To Announce Second-Quarter 2019 Financial Results On July 31

Vertex To Announce Second-Quarter 2019 Financial Results On July 31

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2019 financial results on Wednesday, July 31, 2019 after the financial markets close.

Vertex Expands Into New Disease Areas And Enhances Gene Editing Capabilities Through Expanded Collaboration With CRISPR Therapeutics And Acquisition Of Exonics Therapeutics

Vertex Expands Into New Disease Areas And Enhances Gene Editing Capabilities Through Expanded Collaboration With CRISPR Therapeutics And Acquisition Of Exonics Therapeutics

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the company is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) by expanding its...

Vertex To Present Data At ECFS Conference On Potential Impact Of Early Treatment And Long-Term Treatment With CFTR Modulators On The Underlying Cause Of CF

Vertex To Present Data At ECFS Conference On Potential Impact Of Early Treatment And Long-Term Treatment With CFTR Modulators On The Underlying Cause Of CF

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from six scientific abstracts from the company's portfolio of cystic fibrosis (CF) medicines will be presented at the 42 nd European Cystic Fibrosis Conference, taking place June...

Vertex Selects Triple Combination Regimen Of VX-445, Tezacaftor And Ivacaftor To Submit For Global Regulatory Approvals In Cystic Fibrosis

Vertex Selects Triple Combination Regimen Of VX-445, Tezacaftor And Ivacaftor To Submit For Global Regulatory Approvals In Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has selected the triple combination of the next-generation corrector VX-445 (elexacaftor), tezacaftor and ivacaftor to submit for potential global regulatory approvals for people...

Vertex And Kymera Therapeutics Establish Strategic Collaboration To Discover And Develop Targeted Protein Degradation Medicines For Serious Diseases

Vertex And Kymera Therapeutics Establish Strategic Collaboration To Discover And Develop Targeted Protein Degradation Medicines For Serious Diseases

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Kymera Therapeutics today announced that the two companies have entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple...

Noteworthy Friday Option Activity: VRTX, AAXN, TRXC

Noteworthy Friday Option Activity: VRTX, AAXN, TRXC

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Vertex Pharmaceuticals, Inc. , where a total of 8,194 contracts have traded so far, representing approximately 819,400 underlying shares.

Vertex Reports First-Quarter 2019 Financial Results

Vertex Reports First-Quarter 2019 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2019 and reiterated full-year 2019 financial guidance.

TheStreet Quant Rating: B (Buy)